VCP ScannerFree US Stock Screener & Financial AnalysisFree US Stock Screener
ScreenerThemesMarketEarningsCompareWatchlistInsider
PTCTPTC Therapeutics, Inc.
$78.98$6.6B
Research
Overview
Valuation
ValuationTargetsPrice
Financials
RevenueEarningsP/ERatiosDividend
Ownership
Holders
Tools
Total ReturnDCA Calculator
← Back to Screener
VCP ScannerFree US Stock Screener & Financial Analysis

Find stocks. Verify deeply. Act with conviction.

Data updated daily

Product

  • Screener
  • Themes
  • Valuation
  • Total Return
  • DCA Calculator
  • News
  • Earnings

Resources

  • Market Valuation
  • Compare
  • Insider Activity
  • Methodology
  • How It Works
  • Glossary
  • Learn

Get Ideas

Get weekly stock ideas — free

Follow VCP Scanner on XFollow VCP Scanner on LinkedIn
© 2026 VCP Scanner
AboutPrivacyTerms
Not financial advice. Do your own research.
ScreenerNewsCompareWatchlist
HomeStocksPTCTEarnings History

PTCT logoPTC Therapeutics, Inc. (PTCT) Earnings History

Net Loss

15 years of earnings data (2011–2025) · Currently unprofitable on a TTM basis

TTM Net Income
-$187M
● Net Loss
TTM EPS (Diluted)
$-2.26
Per share, diluted
YoY EPS Growth
+264.5%
Excellent
Net Margin
39.4%
After-tax profitability
EPS Growth Rate (CAGR)
1YN/A
3YN/A
5YN/A
10YN/A
Operating Margin49.5%
Gross Margin95.9%
Return on EquityN/A
Return on Assets29.6%
Record Annual Net Income$683MFY2025
Record Quarterly EPS$10.04Q1 2025
Consecutive Profitable Years1years
Q1 2026
Net Income-$3M
EPS (Diluted)$-0.03
YoY Growth+264.5%Excellent
QoQ Growth+97.9%Excellent

Loading earnings history...

PTC Therapeutics, Inc. (PTCT) Earnings Overview

As of June 22, 2026, PTC Therapeutics, Inc. (PTCT) reported trailing twelve-month net income of -$187M, reflecting +264.5% year-over-year growth. The company earned $-2.26 per diluted share over the past four quarters, with a net profit margin of 39.4%.

Looking at the long-term picture, PTCT's historical earnings data spans multiple years. The company achieved its highest annual net income of $683M in fiscal 2025, representing a new all-time high.

PTC Therapeutics, Inc. is currently reporting a net loss, though operating performance should be evaluated in the context of growth investments and industry dynamics View revenue history →

Compared to peers including SRPT ($65M net income, -32.5% margin), BMRN ($269M net income, 10.8% margin), RARE (-$609M net income, -85.4% margin), PTCT has outperformed on profitability metrics. Compare PTCT vs SRPT →

PTCT Earnings vs Peers

Earnings metrics vs comparable public companies

CompanyTTM Net IncomeTTM EPSNet MarginROEYoY GrowthCompare
PTCT logoPTCTCurrent
-$187M$-2.2639.4%-+264.5%—
SRPT logoSRPT
$65M$0.53-32.5%-53.5%-404.7%
BMRN logoBMRN
$269M$1.3610.8%5.9%-18.6%
RARE logoRARE
-$609M$-6.06-85.4%-607.5%+7.3%
ALNY logoALNY
$577M$4.188.4%73.3%+206.9%
ACAD logoACAD
$376M$2.1836.5%39.9%+68.4%
Best in group
Lowest in group

PTCT Historical Earnings Data (2011–2025)

15 years
Fiscal Year Net Income YoY % Operating Income EPS (Diluted) Net Margin Op. Margin
2025$683M+287.9%$857M$7.7839.4%49.5%
2024-$363M+42.0%-$303M$-4.73-45.0%-37.5%
2023-$627M-12.1%-$440M$-8.37-66.8%-46.9%
2022-$559M-6.7%-$447M$-7.79-80.0%-64.0%
2021-$524M-19.6%-$374M$-7.43-97.3%-69.5%
2020-$438M-74.2%-$432M$-6.64-115.1%-113.4%
2019-$252M-96.4%-$241M$-4.27-82.0%-78.6%
2018-$128M-62.1%-$116M$-2.75-48.4%-43.7%
2017-$79M+44.4%-$64M$-2.02-40.6%-33.1%
2016-$142M+16.6%-$132M$-4.17-171.8%-159.7%
2015-$170M-81.8%-$167M$-5.07-463.6%-454.6%
2014-$94M-81.8%-$99M$-2.97-408.3%-432.9%
2013-$52M-96.6%-$45M$-4.02-164.6%-144.9%
2012-$26M-184.9%-$27M$-1.11-91.2%-93.2%
2011$31M-$31M$0.0031.2%30.9%

Download Data

Export PTCT earnings history in CSV or JSON format

Free sign-in required to download data

Consensus-Based Analysis Tools

Intrinsic Valuation

DCF models, multiple analysis, and analyst estimates.

Check Valuation

Historical Returns

15+ years return with dividends reinvested.

Calculate

DCA Calculator

See how regular investing compounds over time.

Run Numbers

Peer Comparison

Compare growth, multiples, and margins vs sector.

Compare

PTCT — Frequently Asked Questions

Quick answers to the most common questions about buying PTCT stock.

What is PTCT earnings per share (EPS)?

PTCT trailing twelve-month (TTM) diluted EPS is $-2.26, reflecting +264.5% year-over-year growth. The 5-year EPS CAGR is N/A. Complete EPS history from 2011 to 2025 is available in the table on this page.

What is PTC Therapeutics, Inc.'s net income?

PTC Therapeutics, Inc. (PTCT) trailing twelve-month net income is $-187M as of 2025. Earnings grew +264.5% year-over-year.

Is PTCT profitable?

PTCT is not currently profitable on a TTM basis, reporting a net loss of $-187M. Net margin is +39.4%. Investors should monitor for a return to profitability.

What is PTCT's earnings growth rate?

PTCT compound annual EPS growth rates (CAGR): 1-Year: N/A, 3-Year: N/A, 5-Year: N/A, 10-Year: N/A. These figures measure the annualised rate of diluted EPS growth over each period, based on data from 2011 to 2025.

What are PTCT's profit margins?

PTC Therapeutics, Inc. net profit margin is +39.4%, operating margin is +49.5%, and gross margin is +95.9%. Above-average net margins reflect strong pricing power and competitive moat. Return on Equity is N/A.

Is PTCT growing earnings?

Yes, PTCT earnings are accelerating — EPS growth of +264.5% exceeds the 5-year CAGR of N/A. TTM net income reached $-187M. Earnings momentum is strengthening.

What was PTCT's best earnings year?

PTC Therapeutics, Inc.'s highest annual net income on record is $683M, achieved in fiscal year 2025. Earnings history on this page spans 2011 to 2025 and includes all annual and quarterly figures.

What were PTCT's earnings last quarter?

PTCT's most recent reported quarter was Q1 2026. Net income was $-3M with diluted EPS of $-0.03. For a full breakdown of all quarters, see the quarterly earnings table on this page.

PTCT Earnings Over Time (2011–2025)

Net income & EPS — annual and quarterly view